Prestige Consumer Healthcare (NYSE:PBH) Stock Bumped Down to “Hold” by Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks reports.

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $67.67.

Prestige Consumer Healthcare Price Performance

PBH opened at $49.08 on Thursday. The firm has a market cap of $2.33 billion, a P/E ratio of 11.03, a PEG ratio of 1.53 and a beta of 0.34. The firm has a 50-day moving average of $48.54 and a 200 day moving average of $54.20. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. Prestige Consumer Healthcare has a fifty-two week low of $42.62 and a fifty-two week high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to analysts’ expectations of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%. The business’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, research analysts expect that Prestige Consumer Healthcare will post 4.56 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Covestor Ltd increased its position in shares of Prestige Consumer Healthcare by 45.6% during the third quarter. Covestor Ltd now owns 1,589 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares during the period. Profund Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 356.2% in the third quarter. Profund Advisors LLC now owns 33,690 shares of the company’s stock valued at $1,545,000 after purchasing an additional 26,305 shares during the period. Vise Technologies Inc. purchased a new stake in shares of Prestige Consumer Healthcare in the third quarter valued at approximately $250,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Prestige Consumer Healthcare in the third quarter worth approximately $216,000. Finally, Choreo LLC grew its stake in Prestige Consumer Healthcare by 14.8% in the third quarter. Choreo LLC now owns 20,376 shares of the company’s stock worth $935,000 after purchasing an additional 2,632 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc (NYSE: PBH) is a consumer healthcare company that develops, acquires, markets and distributes over-the-counter health and wellness products. Its portfolio is focused on established brands designed to address everyday healthcare needs, including digestive health, eye and ear care, oral care, pain relief, cold and allergy symptoms, feminine care and dermatological conditions.

The company’s brands include Dramamine and Bonine for motion-sickness relief; BC and Goody’s for pain relief; Clear Eyes and Murine for eye and ear care; Chloraseptic for sore-throat relief; Compound W for wart removal; Fleet for gastrointestinal health; and Summer’s Eve for feminine care.